J&J: licensing agreement with Korea's LegoChem in ADCs
Under the terms of the agreement, Innate has received an upfront payment of $100 million, and will be entitled to receive up to a further $200 million if the option for LCB84 is exercised.
Taking into account development, regulatory and commercial milestone payments, LegoChem estimates that it could receive total royalties of $1.7 billion on potential sales of the product.
LCB84, currently in Phase 1/2 clinical trials in the U.S., features a differentiated mechanism of action, as it targets the Trop2 antigen, highly expressed in cancer cells.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction